Amarantus Licenses Power3 Test for Parkinson's Disease | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Amarantus BioSciences today said that it has licensed exclusive, worldwide rights from Power3 Medical Products to a test for Parkinson's disease diagnosis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.